Labcorp Holdings Inc. (NYSE:LH) Receives $307.70 Average PT from Analysts

Shares of Labcorp Holdings Inc. (NYSE:LH) have received an average rating of “Moderate Buy” from the eleven research firms that are covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $307.20.

Several analysts have recently weighed in on LH shares. Evercore reissued an “outperform” rating and set a $300.00 price objective on shares of Labcorp in a report on Wednesday, April 8th. Morgan Stanley reissued an “overweight” rating on shares of Labcorp in a report on Tuesday, February 17th. JPMorgan Chase & Co. lifted their price objective on Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Robert W. Baird lifted their price objective on Labcorp from $313.00 to $326.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Finally, Weiss Ratings raised Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, February 10th.

Insider Buying and Selling

In related news, EVP Brian J. Caveney sold 1,500 shares of the business’s stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $286.31, for a total value of $429,465.00. Following the sale, the executive vice president owned 30,107 shares of the company’s stock, valued at $8,619,935.17. The trade was a 4.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jonathan C. Meltzer sold 87 shares of the business’s stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $290.42, for a total value of $25,266.54. Following the completion of the sale, the executive vice president directly owned 2,782 shares in the company, valued at approximately $807,948.44. This represents a 3.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 16,113 shares of company stock worth $4,547,450 in the last quarter. Corporate insiders own 0.84% of the company’s stock.

Institutional Trading of Labcorp

Several institutional investors have recently bought and sold shares of LH. Victory Capital Management Inc. boosted its stake in Labcorp by 103.1% in the 4th quarter. Victory Capital Management Inc. now owns 5,356,825 shares of the medical research company’s stock valued at $1,343,922,000 after buying an additional 2,719,475 shares in the last quarter. Boston Partners acquired a new stake in Labcorp in the 4th quarter valued at $480,271,000. Norges Bank acquired a new stake in Labcorp in the 4th quarter valued at $248,006,000. Lazard Asset Management LLC raised its position in Labcorp by 224.1% in the 2nd quarter. Lazard Asset Management LLC now owns 989,433 shares of the medical research company’s stock valued at $259,734,000 after purchasing an additional 684,153 shares during the last quarter. Finally, Pacer Advisors Inc. raised its position in Labcorp by 4,070.6% in the 3rd quarter. Pacer Advisors Inc. now owns 305,746 shares of the medical research company’s stock valued at $87,767,000 after purchasing an additional 298,415 shares during the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Labcorp Price Performance

Shares of NYSE:LH opened at $264.46 on Thursday. Labcorp has a 1-year low of $209.38 and a 1-year high of $293.72. The firm has a market capitalization of $21.79 billion, a PE ratio of 25.28, a PEG ratio of 1.79 and a beta of 1.02. The business’s 50 day moving average is $274.28 and its 200-day moving average is $268.56. The company has a current ratio of 1.42, a quick ratio of 1.23 and a debt-to-equity ratio of 0.60.

Labcorp (NYSE:LH) last announced its quarterly earnings data on Tuesday, February 17th. The medical research company reported $4.07 earnings per share for the quarter, topping the consensus estimate of $3.95 by $0.12. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The company had revenue of $3.52 billion for the quarter, compared to analyst estimates of $3.56 billion. During the same quarter last year, the firm earned $3.45 EPS. Labcorp’s revenue for the quarter was up 5.6% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. Sell-side analysts predict that Labcorp will post 16.01 earnings per share for the current year.

Labcorp Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Friday, May 29th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Friday, May 29th. This represents a $2.88 annualized dividend and a yield of 1.1%. Labcorp’s payout ratio is currently 27.53%.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.